SCHEMBL1158683

SCHEMBL1158683

Cc1ccnc(Nc2cc3cc[nH]c(=O)c3c(NC3CCOCC3)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 5/20 0.51
▸ FER P16591 1/20 0.45
▸ JAK2 O60674 4/20 0.44
▸ JAK1 P23458 1/20 0.44
▸ ZAP70 P43403 8/20 0.43
▸ LYN P07948 3/20 0.43
▸ KCNH2 Q12809 2/20 0.43
▸ FLT3 P36888 1/20 0.43
▸ PDE5A O76074 1/20 0.41
▸ LRRK2 Q5S007 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.38
▸ BRD4 O60885 2/20 0.38
▸ ATAD2 Q6PL18 2/20 0.38
▸ IRAK4 Q9NWZ3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158786 0.94 SYK (0.48) SYKFERJAK2JAK1ZAP70
SCHEMBL1158651 0.94 SYK (0.48) SYKFERJAK2JAK1ZAP70
SCHEMBL1158252 0.94 SYK (0.48) SYKFERJAK2JAK1ZAP70
SCHEMBL1158534 0.93 SYK (0.58) SYKFERJAK2ZAP70LYN
SCHEMBL1158606 0.91 SYK (0.54) SYKFERJAK2JAK1ZAP70
SCHEMBL1158890 0.91 SYK (0.54) SYKFERJAK2JAK1ZAP70
SCHEMBL1158767 0.89 SYK (0.64) SYKFERJAK2ZAP70LYN
SCHEMBL12795693 0.89 SYK (0.64) SYKFERJAK2ZAP70LYN
SCHEMBL1158647 0.89 SYK (0.56) SYKFERJAK2ZAP70LYN
SCHEMBL1158617 0.87 SYK (0.49) SYKFERJAK2ZAP70LYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 — — EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 — — WO disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN SYK 1/4885FER 89/4885JAK2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback